Effects of intravenous infusion of hydrogen-rich fluid combined with intra-cisternal infusion of magnesium sulfate in severe aneurysmal subarachnoid hemorrhage: a randomized controlled trial

Effects of intravenous infusion of hydrogen-rich fluid combined with intra-cisternal infusion of magnesium sulfate in severe aneurysmal subarachnoid hemorrhage: a randomized controlled trial - Effects of intravenous infusion of hydrogen-rich fluid combined with intra-cisternal infusion of magnesium sulfate in severe aneurysmal subarachnoid hemorrhage: a randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014696

Enrollment

450

Registered

2014-07-29

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Interventions

intravenous hydrogen-rich fluid infusion with intra-cisternal magnesium sulfate infusion intra-cisternal magnesium sulfate infusion only placebo (control group)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) subarachnoid hemorrhage due to aneurysm rupture (Hunt and Kosnik grade 4 or 5) (2) aneurysm treated by surgical clipping within 72 hours after the onset (3) written informed consent from the patient or family member

Exclusion criteria

Exclusion criteria: (1) severe brain edema (2) heart dysfunction (New York Heart Association Class III or IV) (3) renal insufficiency (calculated creatinine clearance rate of less than 30 mL/min), Fisher grade 4 with massive intracerebral hematoma, and rejection of randomization.

Design outcomes

Primary

Measure	Time frame
(1) Occurrence of delayed cerebral ischemia (2) Occurrence of cerebral vasospasm	—

Secondary

Measure	Time frame
(1) Modified Rankin scale score at 3, 6, and 12 months (2) Biochemical markers (malondialdehyde, neuron-specific enolase, S-100 calcium binding protein B, and C-reactive protein)	—

Countries

Japan

Contacts

Public ContactSatoru Takeuchi

National Defense Medical College Department of Neurosurgery

s.takeuchi@room.ocn.ne.jp042-995-1511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026